Correction Open Access
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2021; 9(20): 5752-5753
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5752
Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
Li-Xuan Sang, Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China
ORCID number: Li-Xuan Sang (0000-0002-4562-0022).
Author contributions: Sang LX solely contributed to this paper.
Conflict-of-interest statement: No conflicts of intererest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xuan Sang, PhD, Associate Professor, Department of Geriatrics, the First Affiliated Hospital, China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. sanglixuan2008@163.com
Received: January 11, 2021
Peer-review started: January 11, 2021
First decision: April 29, 2021
Revised: May 7, 2021
Accepted: May 24, 2021
Article in press: May 24, 2021
Published online: July 16, 2021

Abstract

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8: 1361-1384. We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.

Key Words: Correction, Probiotic mixture VSL#3, Intestinal barrier function, Chronic diseases, Cytokines, Therapeutic use

Core Tip: This manuscript is to further explain VSL#3 mentioned in it for probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases (World J Clin Cases 2020; 8: 1361-1384).
CORRECTION

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8: 1361-1384 PMID: 32368530 DOI: 10.12998/wjcc.v8.i8.1361.

We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. We published an article about probiotic mixture VSL#3 on April 26, 2020. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.

Footnotes

Manuscript source: Unsolicited Manuscript

Specialty type: Gastroenterology and Hepatology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Chae Y S-Editor: Zhang L L-Editor: A P-Editor: Yuan YY

References
1.  Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8:1361-1384.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 50]  [Cited by in F6Publishing: 57]  [Article Influence: 14.3]  [Reference Citation Analysis (4)]